Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) receptor , is showing promising data in initial human trials . Recent research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/